Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 15

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 15
---
, even if they are approved by the regulatory
authorities. The degree of market acceptance of any of our approved drug candidates will depend on a variety of factors, including:

  timing of market introduction, number and clinical profile of competitive products;  

  our ability to provide acceptable evidence of safety and efficacy and our ability to secure the support of key clinicians and physicians for our drug candidates;  

  cost-effectiveness compared to existing and new treatments;  

  availability of coverage, reimbursement and adequate payment from health maintenance organizations and other third party payers;  

  prevalence and severity of adverse side effects; and  

  other advantages over other treatment methods.  

Physicians, patients, payers
or the medical community may be unwilling to accept, use or recommend our drug candidates, which would adversely affect our potential
revenues and future profitability. Adverse publicity or public perception regarding our drug candidates may negatively influence the success
of these therapies.

We face competition from entities that may develop drug candidates
for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology
similar to ours.

The development and commercialization
of drug candidates is highly competitive. Multinational pharmaceutical companies and specialized biotechnology companies could develop
drug candidates and processes competitive with our drug candidates. Competitive therapeutic treatments include those that have already
been approved and accepted by the medical community, patients and third party payers, and any new treatments that enter the market.

There may be a significant
number of products that are currently under development, and may become commercially available in the future, for the treatment of conditions
for which we are developing, and may in the future try to develop, drug candidates.

Multinational pharmaceutical
companies and specialized biotechnology companies could have significantly greater financial, technical, manufacturing, marketing, sales
and supply resources and experience than we have. If we successfully obtain approval for any drug candidate, we could face competition
based on many different factors, including the safety and effectiveness of our drug candidates, the ease with which our drug candidates
can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory
approvals for these drug candidates, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement
coverage and patent position.

Competing products could present
superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any
products we may develop. Competitive products may make any products we develop obsolete